Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor announced final Phase 1 results for XmAb942 showing a 74.1-day half-life that supports a 12-week dosing interval, positioning it as a potential best-in-class treatment for ulcerative colitis. Enrollment in the global Phase 2b XENITH-UC study remains on track for approximately 220 patients, with an interim analysis expected by year-end 2026 and primary results in the second half of 2027.
Key figures
- Drug Name
- XmAb942
- Phase Of Trial
- Phase 1
- Half life days
- 74.1
- Phase2b patients
- approximately 220
- Dosing interval weeks
- 12
- Ada incidence all doses
- 57%
- Ada incidence high dose
- 25%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.